SecBot SecBot
S-3ASR ·Filed May 13, 2026

RLMD

RELMADA THERAPEUTICS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001213900-26-055901
Notable filing: S-3ASR
Actionable Insight ▼ Bearish

The S-3ASR itself is not an immediate offering, but the pattern of frequent dilutive raises (Nov 2025, March 2026, now shelf registration) signals persistent capital needs ahead of mid-2026 clinical catalysts. Monitor for prospectus supplements that would indicate an actual offering, any ATM or follow-on at current prices (~$7.45) would be significantly dilutive given the 43% share count increase already this year. The company's $234M cash position provides runway but the shelf registration suggests management expects to tap markets again before clinical data readouts.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.42
T+0 close · May 13, 2026 · via day close
Latest settled
−38.81%
T+60 · $4.54
Vs SPY
−42.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $7.42entry
  2. T+1 · 6mo ago −7.01%α −5.78% · $6.90
  3. T+5 · 6mo ago −2.83%α −2.11% · $7.21
  4. T+20 · 5mo ago −10.38%α −9.52% · $6.65
  5. T+60 · 3mo ago −38.81%α −42.40% · $4.54

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, registering an indeterminate amount of securities for potential future offerings. The filing comes one day after the company reported Q1 2026 results showing a net loss of $19.1M and a cash position of $234M (including $224M in short-term investments), following a $160M PIPE in March 2026. The shelf registration is an opportunistic capital-raising tool for a clinical-stage biotech with no revenue, but the proximity to the recent large PIPE and the company's history of frequent dilutive raises (November 2025 and March 2026) signals ongoing capital needs ahead of mid-2026 Phase 3/Phase 2b trial initiations.

Key Facts

  • Filed S-3ASR on May 13, 2026, registering an indeterminate amount of common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts, and units
  • Registration includes $50M of unsold securities carried forward from prior S-3 (File No. 333-281877)
  • Q1 2026 net loss of $19.1M ($0.22/share) vs. $17.6M loss in Q1 2025
  • Cash and short-term investments of $234M as of March 31, 2026, up from $93M at year-end 2025 after $160M PIPE in March 2026
  • Company has raised ~$250M in equity in the past 6 months (Nov 2025: ~$94M, March 2026: ~$150M)
  • Outstanding shares increased from 73.3M at Dec 2025 to 104.9M at March 2026, a 43% increase
  • Pre-funded warrants outstanding for 7.4M shares at $0.001 exercise price, plus 8.0M regular warrants at $2.10 weighted average exercise price
  • Stock closed at $7.45 on May 12, 2026, with market cap of $781M
  • Company expects to initiate Phase 3 programs for NDV-01 and Phase 2b study for Sepranolone mid-2026

Financial Impact

Indeterminate offering size, no specific dollar amount registered. Company has $234M cash runway but has raised ~$250M in two equity offerings over 6 months, suggesting ongoing capital needs. Potential dilution could be material if full shelf is utilized.

dilutionshare countcash position

Risk Factors

  • Potential future dilution from shelf offerings, company has raised ~$250M in 6 months and may need more capital before mid-2026 trial initiations
  • Pre-funded warrants (7.4M shares at $0.001) represent near-certain future dilution
  • No revenue and growing operating losses ($19.1M in Q1 2026 vs. $17.6M in Q1 2025)
  • Clinical-stage biotech with no approved products, all pipeline candidates are early-stage (Phase 2/2b)
  • History of failed programs (REL-1017 terminated July 2025, REL-P11 terminated May 2025)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001213900-26-055901
Document: ea029017201ex-fee.htm0001213900-26-055901
Document: ea029017201ex5-1.htm0001213900-26-055901
Document: ea029017201ex23-2.htm0001213900-26-055901
Document: ea029017201ex23-1.htm0001213900-26-055901
Document: 0001213900-26-055901-index-headers.html0001213900-26-055901
Document: 0001213900-26-055901-index.html0001213900-26-055901
Document: 0001213900-26-055901.txt0001213900-26-055901

Track record

11 reports on RLMD

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Viewing Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026